Model 4296 Left Ventricular (LV) Lead Chronic Performance Study

NCT ID: NCT01361672

Last Updated: 2019-07-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-05-31

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lead survivability will be summarized.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate long-term performance of the 4296 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4296 LV Lead. This study is conducted within Medtronic's post-market surveillance platform.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
* Patient has or is intended to receive an Attain Ability Model 4296 LV lead
* Patient within 30 day post implant enrollment window

Exclusion Criteria

* Patient who is, or is expected to be inaccessible for follow-up
* Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Anchorage, Alaska, United States

Site Status

Chandler, Arizona, United States

Site Status

Gilbert, Arizona, United States

Site Status

Phoenix, Arizona, United States

Site Status

Jonesboro, Arkansas, United States

Site Status

Little Rock, Arkansas, United States

Site Status

Bakersfield, California, United States

Site Status

Chula Vista, California, United States

Site Status

Monterey, California, United States

Site Status

Rancho Mirage, California, United States

Site Status

Redding, California, United States

Site Status

Redwood City, California, United States

Site Status

Salinas, California, United States

Site Status

San Diego, California, United States

Site Status

San Francisco, California, United States

Site Status

Stanford, California, United States

Site Status

Torrance, California, United States

Site Status

Van Nuys, California, United States

Site Status

Colorado Springs, Colorado, United States

Site Status

Lakewood, Colorado, United States

Site Status

New Haven, Connecticut, United States

Site Status

Newark, Delaware, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Bradenton, Florida, United States

Site Status

Clearwater, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Melbourne, Florida, United States

Site Status

Safety Harbor, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Indianapolis, Indiana, United States

Site Status

West Des Moines, Iowa, United States

Site Status

Kansas City, Kansas, United States

Site Status

Lexington, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Baton Rouge, Louisiana, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Hyattsville, Maryland, United States

Site Status

Silver Spring, Maryland, United States

Site Status

Takoma Park, Maryland, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Lansing, Michigan, United States

Site Status

Marquette, Michigan, United States

Site Status

Ypsilanti, Michigan, United States

Site Status

Robbinsdale, Minnesota, United States

Site Status

Rochester, Minnesota, United States

Site Status

Saint Louis Park, Minnesota, United States

Site Status

Columbia, Missouri, United States

Site Status

Kansas City, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Henderson, Nevada, United States

Site Status

Las Vegas, Nevada, United States

Site Status

Lebanon, New Hampshire, United States

Site Status

Morristown, New Jersey, United States

Site Status

Ocean City, New Jersey, United States

Site Status

West Orange, New Jersey, United States

Site Status

Albuquerque, New Mexico, United States

Site Status

Garden City, New York, United States

Site Status

Huntington, New York, United States

Site Status

New York, New York, United States

Site Status

Poughkeepsie, New York, United States

Site Status

Utica, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Fargo, North Dakota, United States

Site Status

Akron, Ohio, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Allentown, Pennsylvania, United States

Site Status

Danville, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Lancaster, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Wilkes-Barre, Pennsylvania, United States

Site Status

Columbia, South Carolina, United States

Site Status

Germantown, Tennessee, United States

Site Status

Kingsport, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Plano, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

The Woodlands, Texas, United States

Site Status

Falls Church, Virginia, United States

Site Status

Leesburg, Virginia, United States

Site Status

Olympia, Washington, United States

Site Status

Spokane, Washington, United States

Site Status

Tacoma, Washington, United States

Site Status

Madison, Wisconsin, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Ottawa, Ontario, Canada

Site Status

Peterborough, Ontario, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Québec, Quebec, Canada

Site Status

Essen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4296 Chronic Performance

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Attain Success Clinical Trial
NCT00990964 COMPLETED